Kim Margolin

City Of Hope National Medical Center
United States

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 81 Citations 31,461 340 World Ranking 11221 National Ranking 5877

Overview

What are the main themes of her work throughout her whole career to date

Her research on Internal medicine often connects related topics like Sepsis. Sepsis is closely attributed to Surgery in her research. Surgery is often connected to Regimen in her work. Her study brings together the fields of Internal medicine and Regimen. In her works, she undertakes multidisciplinary study on Gynecology and Oncology. She brings together Oncology and Gynecology to produce work in her papers. Kim Margolin incorporates Cancer and Testicular cancer in her research. While working in this field, Kim Margolin studies both Testicular cancer and Cancer. Chromosome and Cytogenetics are two areas of study in which she engages in interdisciplinary research.

Kim Margolin most often published in these fields:

Internal medicine (100.00%)
Gynecology (50.00%)
Oncology (50.00%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

Michael B. Atkins;Michael T. Lotze;Janice P. Dutcher;Richard I. Fisher.
Journal of Clinical Oncology (1999)

2262 Citations

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Dirk Schadendorf;F. Stephen Hodi;Caroline Robert;Jeffrey S. Weber.
Journal of Clinical Oncology (2015)

1955 Citations

Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Robert J. Motzer;Brian I. Rini;Brian I. Rini;Ronald M. Bukowski;Brendan D. Curti.
JAMA (2006)

1554 Citations

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas;Igor Puzanov;Reinhard Dummer;Dirk Schadendorf.
Lancet Oncology (2015)

1524 Citations

Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer

M. S. Gordon;K. Margolin;M. Talpaz;G. W. Sledge.
Journal of Clinical Oncology (2001)

1326 Citations

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Paul T. Nghiem;Shailender Bhatia;Evan J. Lipson;Ragini R. Kudchadkar.
The New England Journal of Medicine (2016)

1073 Citations

Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial

Kim Margolin;Marc S Ernstoff;Omid Hamid;Donald Lawrence.
Lancet Oncology (2012)

1029 Citations

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

Robert J. Motzer;Brian I. Rini;David F. McDermott;Bruce G. Redman.
Journal of Clinical Oncology (2015)

1026 Citations

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

David F. McDermott;Meredith M. Regan;Joseph I. Clark;Lawrence E. Flaherty.
Journal of Clinical Oncology (2005)

962 Citations

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Hussein A. Tawbi;Peter A. Forsyth;Alain Algazi;Omid Hamid.
The New England Journal of Medicine (2018)

841 Citations

If you think any of the details on this page are incorrect, let us know.